TP53 and head and neck squamous cell carcinoma: Although these results are encouraging and represent a progression in the ongoing debate, the authors acknowledge that broadly assigning a global deleterious contribution of TP53 mutation to poor outcomes irrespective of HNSCC subsite or mutation category would constitute a gross oversimplification of the clinical conundrum.